Dosing & Uses
Dosage Forms & Strengths
tablet
- 0.4mg
Sialorrhea, Pylorospasm & Other Spastic Conditions of the Gastrointestinal Tract
0.4 mg PO q4-6hr PRN
Dosage Forms & Strengths
tablet
- 0.4mg
Sialorrhea, Pylorospasm & Other Spastic Conditions of the Gastrointestinal Tract
3-7 kg: 0.1 mg
8-11 kg: 0.15 mg
11-18 kg: 0.2 mg
18-29 kg: 0.3 mg
≥30 kg: 0.4 mg
Alternate Dosing
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (9)
- eluxadoline
atropine, eluxadoline. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that cause constipation. Increases risk for constipation related serious adverse reactions. .
- glucagon
glucagon increases effects of atropine by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. .
- glucagon intranasal
glucagon intranasal increases effects of atropine by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. .
- glycopyrronium tosylate topical
glycopyrronium tosylate topical, atropine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.
- macimorelin
atropine, macimorelin. unspecified interaction mechanism. Avoid or Use Alternate Drug. Drugs that may blunt the growth hormone (GH) response to macrimorelin may impact the accuracy of the diagnostic test. Allow sufficient washout time of drugs affecting GH release before administering macimorelin.
- pramlintide
pramlintide, atropine. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility.
- revefenacin
revefenacin and atropine both decrease cholinergic effects/transmission. Avoid or Use Alternate Drug. Coadministration may cause additive anticholinergic effects.
- secretin
atropine decreases effects of secretin by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Concomitant use of anticholinergic drugs may cause a hyporesponse to stimulation testing with secretin. Discontinue anticholinergic drugs at least 5 half-lives before administering secretin.
- umeclidinium bromide/vilanterol inhaled
atropine, umeclidinium bromide/vilanterol inhaled. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Concomitant use with other anticholinergic-containing drugs may lead to additive anticholinergic adverse effects.
Monitor Closely (101)
- abobotulinumtoxinA
abobotulinumtoxinA increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects. .
- aclidinium
atropine and aclidinium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- amantadine
atropine, amantadine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Potential for increased anticholinergic adverse effects.
- amitriptyline
atropine and amitriptyline both decrease cholinergic effects/transmission. Modify Therapy/Monitor Closely.
- amoxapine
atropine and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- anticholinergic/sedative combos
anticholinergic/sedative combos and atropine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- aripiprazole
atropine decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
atropine decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.
aripiprazole increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - atracurium
atracurium and atropine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- belladonna alkaloids
atropine and belladonna alkaloids both decrease cholinergic effects/transmission. Use Caution/Monitor.
- belladonna and opium
atropine and belladonna and opium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- benperidol
atropine decreases levels of benperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
atropine decreases levels of benperidol by pharmacodynamic antagonism. Use Caution/Monitor.
benperidol increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - benztropine
atropine and benztropine both decrease cholinergic effects/transmission. Use Caution/Monitor. Additive anticholinergic adverse effects may be seen with concurrent use.
- bethanechol
bethanechol increases and atropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- buprenorphine, long-acting injection
buprenorphine, long-acting injection increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of buprenorphine with anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.
- carbachol
carbachol increases and atropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- cevimeline
cevimeline increases and atropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- chlorpromazine
atropine decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
atropine decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.
chlorpromazine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - cisatracurium
atropine and cisatracurium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- clomipramine
atropine and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- clozapine
atropine decreases levels of clozapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
atropine decreases levels of clozapine by pharmacodynamic antagonism. Use Caution/Monitor.
clozapine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - cyclizine
atropine and cyclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- cyclobenzaprine
atropine and cyclobenzaprine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- darifenacin
atropine and darifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.
- dicyclomine
atropine and dicyclomine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- digoxin
atropine increases levels of digoxin by unknown mechanism. Use Caution/Monitor.
- diphenhydramine
atropine and diphenhydramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- donepezil
donepezil increases and atropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- donepezil transdermal
donepezil transdermal, atropine. Either decreases effects of the other by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.
- dosulepin
atropine and dosulepin both decrease cholinergic effects/transmission. Use Caution/Monitor.
- doxepin
atropine and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor.
- droperidol
atropine decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
atropine decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.
droperidol increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - echothiophate iodide
echothiophate iodide increases and atropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- fentanyl
fentanyl, atropine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.
- fentanyl intranasal
fentanyl intranasal, atropine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.
- fentanyl transdermal
fentanyl transdermal, atropine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.
- fentanyl transmucosal
fentanyl transmucosal, atropine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.
- fesoterodine
atropine and fesoterodine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- flavoxate
atropine and flavoxate both decrease cholinergic effects/transmission. Use Caution/Monitor.
- fluphenazine
atropine decreases levels of fluphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
atropine decreases levels of fluphenazine by pharmacodynamic antagonism. Use Caution/Monitor.
fluphenazine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - galantamine
galantamine increases and atropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- glycopyrrolate
atropine and glycopyrrolate both decrease cholinergic effects/transmission. Use Caution/Monitor.
- glycopyrrolate inhaled
atropine and glycopyrrolate inhaled both decrease cholinergic effects/transmission. Use Caution/Monitor.
- haloperidol
atropine decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
atropine decreases levels of haloperidol by pharmacodynamic antagonism. Use Caution/Monitor.
haloperidol increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - henbane
atropine and henbane both decrease cholinergic effects/transmission. Use Caution/Monitor.
- homatropine
atropine and homatropine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- huperzine A
huperzine A increases and atropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- hyoscyamine
atropine and hyoscyamine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- hyoscyamine spray
atropine and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- iloperidone
atropine decreases levels of iloperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
atropine decreases levels of iloperidone by pharmacodynamic antagonism. Use Caution/Monitor.
iloperidone increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - imipramine
atropine and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- incobotulinumtoxinA
atropine, incobotulinumtoxinA. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.
- ipratropium
atropine and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
- lofepramine
atropine and lofepramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- loxapine
atropine decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
atropine decreases levels of loxapine by pharmacodynamic antagonism. Use Caution/Monitor.
loxapine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - loxapine inhaled
loxapine inhaled increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
atropine decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor. - maprotiline
atropine and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.
- meclizine
atropine and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- methscopolamine
atropine and methscopolamine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- metoclopramide intranasal
atropine will decrease the level or effect of metoclopramide intranasal by Other (see comment). Use Caution/Monitor. Coadministration of metoclopramide intranasal with drugs that impair GI motility may decrease systemic absorption of metoclopramide. Monitor for reduced therapeutic effect.
- neostigmine
neostigmine increases and atropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- nortriptyline
atropine and nortriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.
- olanzapine
atropine decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
atropine decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor.
olanzapine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - oliceridine
atropine increases toxicity of oliceridine by Other (see comment). Use Caution/Monitor. Comment: Anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Monitor for signs of urinary retention or reduced gastric motility if oliceridine is coadministered with anticholinergics.
- onabotulinumtoxinA
atropine and onabotulinumtoxinA both decrease cholinergic effects/transmission. Use Caution/Monitor.
- orphenadrine
atropine and orphenadrine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxybutynin
atropine and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxybutynin topical
atropine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxybutynin transdermal
atropine and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.
- paliperidone
atropine decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
atropine decreases levels of paliperidone by pharmacodynamic antagonism. Use Caution/Monitor.
paliperidone increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - pancuronium
atropine and pancuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- perphenazine
atropine decreases levels of perphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
atropine decreases levels of perphenazine by pharmacodynamic antagonism. Use Caution/Monitor.
perphenazine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - physostigmine
physostigmine increases and atropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- pilocarpine
pilocarpine increases and atropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- pimozide
atropine decreases levels of pimozide by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
atropine decreases levels of pimozide by pharmacodynamic antagonism. Use Caution/Monitor.
pimozide increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - prabotulinumtoxinA
atropine, prabotulinumtoxinA. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.
- pralidoxime
atropine and pralidoxime both decrease cholinergic effects/transmission. Use Caution/Monitor.
- prochlorperazine
atropine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
atropine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.
prochlorperazine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - promethazine
atropine decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
atropine decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.
promethazine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - propantheline
atropine and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.
- protriptyline
atropine and protriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.
- pyridostigmine
pyridostigmine increases and atropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- quetiapine
atropine decreases levels of quetiapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
atropine decreases levels of quetiapine by pharmacodynamic antagonism. Use Caution/Monitor.
quetiapine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - rapacuronium
atropine and rapacuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- rimabotulinumtoxinB
atropine, rimabotulinumtoxinB. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Anticholinergics may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade.
- risperidone
atropine decreases levels of risperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
atropine decreases levels of risperidone by pharmacodynamic antagonism. Use Caution/Monitor.
risperidone increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - rocuronium
atropine and rocuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- scopolamine
atropine and scopolamine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- solifenacin
atropine and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.
- succinylcholine
succinylcholine increases and atropine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- thioridazine
atropine decreases levels of thioridazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
atropine decreases levels of thioridazine by pharmacodynamic antagonism. Use Caution/Monitor.
thioridazine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - thiothixene
atropine decreases levels of thiothixene by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
atropine decreases levels of thiothixene by pharmacodynamic antagonism. Use Caution/Monitor.
thiothixene increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - tiotropium
atropine and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- tolterodine
atropine and tolterodine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- trifluoperazine
atropine decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
atropine decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.
trifluoperazine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - trihexyphenidyl
atropine and trihexyphenidyl both decrease cholinergic effects/transmission. Use Caution/Monitor. Potential for additive anticholinergic effects.
- trimipramine
atropine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- trospium chloride
atropine and trospium chloride both decrease cholinergic effects/transmission. Use Caution/Monitor.
- umeclidinium bromide
umeclidinium bromide and atropine both decrease cholinergic effects/transmission. Use Caution/Monitor. If possible, avoid coadministration of additional anticholinergic agents
- vecuronium
atropine and vecuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- ziprasidone
atropine decreases levels of ziprasidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
atropine decreases levels of ziprasidone by pharmacodynamic antagonism. Use Caution/Monitor.
ziprasidone increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. - zotepine
atropine decreases levels of zotepine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
atropine decreases levels of zotepine by pharmacodynamic antagonism. Use Caution/Monitor.
Minor (25)
- amitriptyline
amitriptyline increases levels of atropine by unknown mechanism. Minor/Significance Unknown.
- amoxapine
amoxapine increases levels of atropine by unknown mechanism. Minor/Significance Unknown.
- atenolol
atropine increases levels of atenolol by unknown mechanism. Minor/Significance Unknown.
- chlorpromazine
chlorpromazine increases toxicity of atropine by unknown mechanism. Minor/Significance Unknown.
- clomipramine
clomipramine increases levels of atropine by unknown mechanism. Minor/Significance Unknown.
- desipramine
atropine and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.
desipramine increases levels of atropine by unknown mechanism. Minor/Significance Unknown. - dimenhydrinate
dimenhydrinate increases toxicity of atropine by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- donepezil
donepezil decreases effects of atropine by pharmacodynamic antagonism. Minor/Significance Unknown.
- doxepin
doxepin increases levels of atropine by unknown mechanism. Minor/Significance Unknown.
- fluphenazine
fluphenazine increases toxicity of atropine by unknown mechanism. Minor/Significance Unknown.
- galantamine
galantamine decreases effects of atropine by pharmacodynamic antagonism. Minor/Significance Unknown.
- imipramine
imipramine increases levels of atropine by unknown mechanism. Minor/Significance Unknown.
- levodopa
atropine, levodopa. Other (see comment). Minor/Significance Unknown. Comment: Anticholinergic agents may enhance the therapeutic effects of levodopa; however, anticholinergic agents can exacerbate tardive dyskinesia. In high dosage, anticholinergics may decrease the effects of levodopa by delaying its GI absorption. .
- lofepramine
lofepramine increases levels of atropine by unknown mechanism. Minor/Significance Unknown.
- maprotiline
maprotiline increases levels of atropine by unknown mechanism. Minor/Significance Unknown.
- nortriptyline
nortriptyline increases levels of atropine by unknown mechanism. Minor/Significance Unknown.
- perphenazine
perphenazine increases toxicity of atropine by unknown mechanism. Minor/Significance Unknown.
- prochlorperazine
prochlorperazine increases toxicity of atropine by unknown mechanism. Minor/Significance Unknown.
- promazine
promazine increases toxicity of atropine by unknown mechanism. Minor/Significance Unknown.
- promethazine
promethazine increases toxicity of atropine by unknown mechanism. Minor/Significance Unknown.
- protriptyline
protriptyline increases levels of atropine by unknown mechanism. Minor/Significance Unknown.
- thioridazine
thioridazine increases toxicity of atropine by unknown mechanism. Minor/Significance Unknown.
- trazodone
atropine and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.
trazodone increases levels of atropine by unknown mechanism. Minor/Significance Unknown. - trifluoperazine
trifluoperazine increases toxicity of atropine by unknown mechanism. Minor/Significance Unknown.
- trimipramine
trimipramine increases levels of atropine by unknown mechanism. Minor/Significance Unknown.
Adverse Effects
Frequency Not Defined
Ataxia
Coma
Confusion
Delirium
Dizziness
Drowsiness
Hallucinations
Headache
Insomnia
Nervousness
Arrhythmia
Flushing
Hypotension
Palpitation
Tachycardia
Dyspnea
Laryngospasm
Pulmonary edema
Bloating
Constipation
Delayed gastric emptying
Loss of taste
Nausea
Paralytic ileus
Vomiting
Xerostomia
Nasal dryness
Fever
Anhidrosis
Urticaria
Rash
Scarlantiniform rash
Urinary hesitancy and retention
Anaphylaxis
Angle closure glaucoma
Blurred vision
Dry eyes
Ocular pressure increased
Warnings
Contraindications
Hypersensitivity to anticholinergic drugs
Narrow-angle glaucoma, synechia (adhesions) between iris and eye lens, myasthenia gravis, obstructive uropathy, paralytic ileus, severe ulcerative colitis, toxic megacolon, acute hemorrhage with cardiovascular instability, thyrotoxicosis
Cautions
Use caution in open-angle glaucoma, hyperthyroidism, BPH, CVD, autonomic neuropathy, HTN, partial obstructive uropathy, toxin-mediated diarrhea, hepatic/renal impairment, tachyarrhythmia, Down syndrome, brain damage in children, salivary secretion disorder, hiatal hernia, reflex esophagitis
Restrict dose to 2-3 mg (0.03-0.04 mg/kg) in patients with ischemic heart disease, to avoid atropine-induced tachycardia, increased myocardial oxygen demand and potential for worsening cardiac ischemia or increasing infarction size
Therapy may precipitate acute glaucoma
Treatment may convert partial organic pyloric stenosis into complete obstruction
May lead to complete urinary retention in patients with prostatic hypertrophy
May cause thickening of bronchial secretions and formation of viscid plugs in patients with chronic lung disease
Pregnancy & Lactation
Pregnancy
Drug readily crosses the placental barrier and enters fetal circulation; there are no adequate data on developmental risk associated with use of atropine in pregnant women; adequate animal reproduction studies have not been conducted with atropine
Lactation
Drug reported to be excreted in human milk; there are no data on effects of atropine on breastfed infant or effects on milk production; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed infant from therapy or from underlying maternal condition
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Antimuscarinic; inhibits action of acetylcholine at parasympathetic sites in smooth muscle, CNS, and secretory glands. Increases cardiac output and dries secretions
Pharmacokinetics
Metabolism: Liver
Half-Life: 2.5 hr
Excretion: Urine
Absorption: 90%
Onset: <1 hr
Duration: 4 hr
Peak plasma time: 1 hr
Peak effect: 2 hr
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| atropine injection - | 0.4 mg/mL vial |  | |
| atropine injection - | 0.4 mg/mL vial |  | |
| atropine injection - | 1 mg/mL vial |  | |
| atropine injection - | 0.4 mg/mL vial |  | |
| atropine injection - | 1 mg/mL vial |  | |
| atropine injection - | 0.4 mg/mL vial |  | |
| atropine injection - | 0.1 mg/mL solution |  | |
| atropine injection - | 0.1 mg/mL solution |  | |
| atropine injection - | 0.05 mg/mL solution |  | |
| atropine injection - | 0.1 mg/mL solution |  | |
| atropine injection - | 0.1 mg/mL solution |  | |
| atropine injection - | 0.1 mg/mL solution |  | |
| atropine injection - | 0.4 mg/mL vial |  | |
| atropine injection - | 0.1 mg/mL solution |  | |
| atropine injection - | 0.4 mg/mL vial |  | |
| atropine injection - | 0.4 mg/mL vial |  | |
| atropine injection - | 0.1 mg/mL solution |  | |
| Isopto Atropine ophthalmic (eye) - | 1 % drops |  | |
| atropine intravenous - | 0.4 mg/mL vial |  | |
| atropine intravenous - | 1 mg/mL vial |  | |
| atropine intravenous - | 1 mg/mL vial |  | |
| atropine ophthalmic (eye) - | 1 % drops |  | |
| atropine ophthalmic (eye) - | 1 % drops |  | |
| atropine ophthalmic (eye) - | 1 % drops |  | |
| atropine ophthalmic (eye) - | 1 % drops |  | |
| atropine ophthalmic (eye) - | 1 % drops |  | |
| atropine ophthalmic (eye) - | 1 % drops |  | |
| atropine ophthalmic (eye) - | 1 % ointment |  |
Copyright © 2010 First DataBank, Inc.
Patient Handout
atropine injection
NO MONOGRAPH AVAILABLE AT THIS TIME
USES: Consult your pharmacist.
HOW TO USE: Consult your pharmacist.
SIDE EFFECTS: Consult your pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Consult your pharmacist.
DRUG INTERACTIONS: Consult your pharmacist.Keep a list of all your medications with you, and share the list with your doctor and pharmacist.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.
NOTES: No monograph available at this time.
MISSED DOSE: Consult your pharmacist.
STORAGE: Consult your pharmacist.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.
Information last revised July 2016. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
